-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on NovoCure, Raises Price Target to $20

Benzinga·05/01/2026 13:22:54
Listen to the news
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and raises the price target from $16 to $20.